CNSP or MBRX Thoughts? Apr. 9, 2020 9:07 AM
Post# of 63696
Apr. 9, 2020 9:07 AM ET|About: CNS Pharmaceuticals, Inc. (CNSP)|By: Douglas W. House, SA News Editor
Thinly traded nano cap CNS Pharmaceuticals (NASDAQ:CNSP) jumps 19% premarket on light volume on the heels of its announced collaboration with WPD Pharmaceuticals to develop several preclinical COVID-19 candidates, including WP112, that WPD in-licensed from Moleculin Biotech (NASDAQ:MBRX) (+5% premarket).
MBRX rocketed 126% yesterday after announcing encouraging results on WP112 in cell culture.
WP112 is a prodrug of 2-DG (a prodrug is an inactive compound that is metabolized in the body to produce the active drug) that Moleculin says may have therapeutic potential in COVID-19 since 2-DG inhibits glycolysis which prevents the coronavirus from replicating. In its normal state, though, it is metabolized too quickly to be effective. WP112 is only metabolized once it is inside the cell, enabling much higher tissue and organ concentrations of 2-DG.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.